Effect of Oxidant Gel and Anti-oxidant Gel on Wound Healing After Gingival Depigmentation

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05837416
Collaborator
(none)
30
1
3
14.1
2.1

Study Details

Study Description

Brief Summary

To evaluate effect of Oxidant (Oxygen Releasing Oral Gel) with Coe-Pak versus Anti-oxidant (Nano-emulsion complex propolis and vitamin C gel) with Coe-Pak on wound healing, pain, patient satisfaction after gingival depigmentation

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Gingival depigmentation is considered a periodontal plastic surgery, in which gingival hyperpigmentation is eliminated. The scalpel surgical method is one of the most cost-effective methods, easiest and does not need broad equipment. However, scalpel surgery leads to bleeding during and after surgery, and the surgical area has to be covered with periodontal dressing for 7-10 days. Periodontal dressings are used around the necks of the teeth and surrounding tissue to cover the wound. Non-eugenol dressings are now the most commonly used periodontal dressings include Coe-Pak, Cross Pack, Peripac, Septopack, PerioCare, Perio Putty and Periogenix. Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a high efficiency nano bio fusion gel containing propolis, nano vitamin C, E and herb extract. Anti-oxidant power of nano Vitamin C (NBF GINGIVAL GEL®) is ten times more effective in hundred times smaller amounts, than Vitamin C by itself. Vitamin C collaboratives with Vitamin E and preserves cell membranes integrity. Propolis has antioxidant effect due to its radical scavenging ability, which was more efficient than antioxidant effect of vitamin C. it also enhances synthesis of collagen due to the presence of iron and zinc elements. it has proven to increase healing of epithelial tissues. The presence of oxygen in Oxygen Releasing Oral Gel (blue®m gel) enhances cellular metabolism, collagen synthesis, antibacterial activity, angiogenesis, revascularization, and the release of growth factors, it also helps keratinized tissue formation and has antimicrobial effects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessor and biostatistician will be blinded.
Primary Purpose:
Treatment
Official Title:
Comparative Study of the Effect of Oxidant Gel and Anti-oxidant Gel on Wound Healing After Gingival Depigmentation. (A Randomized Controlled Clinical Trial)
Actual Study Start Date :
Feb 28, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oxygen Releasing Oral Gel (blue®m) with Coe-Pak dressing

topical application of Oxygen Releasing Oral Gel (blue®m) on the surgical site followed by Coe-Pak immediately after gingival depigmentation surgery, then 1 week postoperatively

Drug: blue®m Gel
Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
Other Names:
  • Oxygen Releasing Oral Gel
  • Experimental: Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) with Coe-Pak dressing

    topical application of Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) on surgical site followed by Coe-Pak immediately after surgery, then 1 week postoperatively

    Drug: NBF GINGIVAL GEL®
    Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
    Other Names:
  • nano bio fusion gingival gel
  • Active Comparator: COE-PAK periodontal dressing only

    Periodontal dressing (COE-PAK) will be applied on surgical site only .

    Drug: COE-PAK™
    It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol

    Outcome Measures

    Primary Outcome Measures

    1. wound healing [Change in healing from baseline up to 4 weeks]

      Assessment of healing using the healing index scale by Landry with scale starting from (1 for very poor healing and 5 excellent healing).Postoperatively clinical photographs will be taken.

    Secondary Outcome Measures

    1. Post-operative Pain Assessment [7 days]

      pain score will be measured at 1st week . Visual Analogue Scale (VAS) will be used to evaluate pain with score starting from 0 (minimal pain ) to 10 ( maximum pain). Questionnaire

    2. Post-operative Pain Assessment [14 days]

      pain score will be measured at 2nd week. Visual Analogue Scale (VAS) will be used to evaluate pain with score starting from 0 (minimal pain ) to 10 ( maximum pain) . Questionnaire

    3. Patient Satisfaction [30 days]

      Questionnaire (yes/no)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age ≥ 18 years with anterior maxillary or mandibular physiologic gingival pigmentation

    • Systemically healthy patients

    • Good oral hygiene, Plaque index less than 15%.

    • Cooperative patients able and accept to come for follow up appointments

    Exclusion Criteria:
    • Any interim intervention that may have affected any of the outcomes of interest.

    • Pregnant and lactating females.

    • Smokers

    • Patients reporting systemic conditions that may cause hyperpigmentation (eg.Addison's disease) or on medications (eg. Corticosteroids)

    • Patients reporting systemic conditions that may compromise healing (eg. Diabetes)

    • Patients with poor oral hygiene.

    • Any known allergies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cairo University Cairo Egypt 11562

    Sponsors and Collaborators

    • Cairo University

    Investigators

    • Study Director: Mona Darhous, PHD, Cairo University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hadeer Metwally Shafik Metwally, Principle investigator, Cairo University
    ClinicalTrials.gov Identifier:
    NCT05837416
    Other Study ID Numbers:
    • 16223
    First Posted:
    May 1, 2023
    Last Update Posted:
    May 1, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hadeer Metwally Shafik Metwally, Principle investigator, Cairo University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 1, 2023